
Sign up to save your podcasts
Or
Join us for an interview with Professor Julio Delgado from the Hospital Clinic de Barcelona (Spain) as he explains the intricate process of CAR T-cell therapy. In this episode, we cover the key steps involved in CAR T, such as patient identification, apheresis, manufacturing, cell infusion and managing post-infusion related toxicities.
Prof Delgado offers expert insights on each component of this complex treatment and discusses possible improvements. He also highlights efforts to shorten vein-to-vein time and the importance of academic and non-profit manufacturing in reducing costs. This conversation offers a solid overview for clinicians and hematologists interested in advanced therapy medicinal products (ATMPs).
Host: Isabel Olivera-Martinez, Medical Writer
Guest: Prof Julio Delgado
This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!
Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
2
11 ratings
Join us for an interview with Professor Julio Delgado from the Hospital Clinic de Barcelona (Spain) as he explains the intricate process of CAR T-cell therapy. In this episode, we cover the key steps involved in CAR T, such as patient identification, apheresis, manufacturing, cell infusion and managing post-infusion related toxicities.
Prof Delgado offers expert insights on each component of this complex treatment and discusses possible improvements. He also highlights efforts to shorten vein-to-vein time and the importance of academic and non-profit manufacturing in reducing costs. This conversation offers a solid overview for clinicians and hematologists interested in advanced therapy medicinal products (ATMPs).
Host: Isabel Olivera-Martinez, Medical Writer
Guest: Prof Julio Delgado
This episode is part of a series recorded at the joint EHA-EBMT 6th European CAR T-cell meeting in Valencia in February 2024, more podcasts will be available in the future. Stay tuned!
Interested in more content related to CART? We've got you covered. Check out free CART program on EHA Campus.
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Provide Feedback
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
https://ehaedu.org/Campus
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: [email protected]
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe
763 Listeners
90,812 Listeners
321 Listeners
26 Listeners
3,320 Listeners
3 Listeners
744 Listeners
14,537 Listeners
48 Listeners
28 Listeners
165 Listeners
48 Listeners
20,662 Listeners
0 Listeners
0 Listeners